SFSIG
VRTX icon

San Francisco Sentry Investment Group’s Vertex Pharmaceuticals VRTX Stock Holding History

San Francisco Sentry Investment Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$4K Hold
22
– – ﹤0.01% 596
2021
Q1 		$5K Hold
22
– – ﹤0.01% 602
2020
Q4 		$5K Hold
22
– – ﹤0.01% 568
2020
Q3 		$6K Hold
22
– – ﹤0.01% 531
2020
Q2 		$6K Sell
22
-22
-50% -$5.96K ﹤0.01% 530
2020
Q1 		$10K Hold
44
– – 0.01% 481
2019
Q4 		$10K Sell
44
-122
-73% -$24.7K ﹤0.01% 566
2019
Q3 		$28K Sell
166
-74
-31% -$13.1K 0.01% 448
2019
Q2 		$44K Hold
240
– – 0.02% 389
2019
Q1 		$44K Sell
240
-40
-14% -$7.39K 0.02% 405
2018
Q4 		$46K Sell
280
-21
-7% -$3.64K 0.02% 381
2018
Q3 		$58K Sell
301
-804
-73% -$143K 0.02% 382
2018
Q2 		$188K Sell
1,105
-1
-0.1% -$155 0.08% 214
2018
Q1 		$180K Buy
1,106
+800
+261% +$131K 0.05% 288
2017
Q4 		$46K Buy
306
+94
+44% +$13.9K 0.01% 463
2017
Q3 		$32K Sell
212
-42
-17% -$6.32K 0.01% 488
2017
Q2 		$33K Buy
+254
New +$30.6K 0.01% 405
2014
Q3 		– Sell
-141
Closed -$13K – 654
2014
Q2 		$13K Sell
141
-72
-34% -$5.05K 0.01% 454
2014
Q1 		$15K Hold
213
– – ﹤0.01% 480
2013
Q4 		$16K Hold
213
– – 0.01% 449
2013
Q3 		$16K Hold
213
– – 0.01% 425
2013
Q2 		$17K Buy
+213
New +$15.7K 0.01% 426

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

San Francisco Sentry Investment Group's VRTX Position: Q2 2021 in Review

San Francisco Sentry Investment Group held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2021 at 22 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #596.

San Francisco Sentry Investment Group first reported a position in VRTX in Q2 2013 and has held it in 22 quarters since. The position peaked at $188K in Q2 2018. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

  • San Francisco Sentry Investment Group held 22 shares of Vertex Pharmaceuticals worth $4K as of Q2 2021.
  • San Francisco Sentry Investment Group left its Vertex Pharmaceuticals share count unchanged in Q2 2021.
  • Vertex Pharmaceuticals made up ﹤0.01% of San Francisco Sentry Investment Group's portfolio in Q2 2021, its #596 holding.
  • San Francisco Sentry Investment Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 22 quarters since.
  • San Francisco Sentry Investment Group's Vertex Pharmaceuticals position peaked at $188K in Q2 2018.
  • 976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.